Pancreatic Cancer Trial, Recruiting NCT06801899 Sponsor: Insel Gruppe AG, University Hospital Bern Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06801899
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are scheduled to have a specific type of major abdominal surgery (called a Whipple procedure) for a suspected or confirmed removable tumour of the pancreas, the lower bile duct, or a particular type of tumour at the point where the bile duct meets the small intestine
  • People whose imaging scans (CT, MRI, or ultrasound) suggest that the connection made during surgery between the pancreas and the digestive tract carries a high risk of developing a leak after the operation
  • People who are willing and able to provide written consent to participate in the trial

Who may not be able to join:

  • People whose tumour is a type of duodenal cancer, a certain subtype of ampullary cancer (intestinal type), a neuroendocrine tumour, a non-cancerous tumour, or who have chronic inflammation of the pancreas
  • People whose medical condition means the trial team considers them unable to understand the nature or consequences of taking part in the trial
  • People who are pregnant (women who could potentially become pregnant will need to have a pregnancy blood test before joining)
  • People who are unable to follow the study procedures for reasons such as psychological difficulties or dementia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anna S Wenning, MD, PhD, Department of Visceral Surgery and Medicine Inselspital, Bern University Hospital

Phone: +41 (0)31 632 71 41

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Insel Gruppe AG, University Hospital Bern
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 October 2030

Where this trial is recruiting

🇩🇪 Germany 🇨🇭 Switzerland

Primary endpoints

Overall survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov